...
首页> 外文期刊>Drug Design, Development and Therapy >Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells
【24h】

Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells

机译:耐药性结肠癌细胞产生高癌胚抗原,可能不是引发癌症的细胞

获取原文
           

摘要

Purpose: We evaluated the higher levels of carcinoembryonic antigen (CEA) secreted by the LoVo human colon carcinoma cells in a medium containing anticancer drugs. Drug-resistant LoVo cells were analyzed by subcutaneously xenotransplanting them into mice. The aim of this study was to evaluate whether the drug-resistant cells isolated in this study were cancer-initiating cells, known also as cancer stem cells (CSCs).Methods: The production of CEA was investigated in LoVo cells that were cultured with 0–10 mM of anticancer drugs, and we evaluated the increase in CEA production by the LoVo cells that were stimulated by anticancer drug treatment. The expression of several CSC markers in LoVo cells treated with anticancer drugs was also evaluated. Following anticancer drug treatment, LoVo cells were injected subcutaneously into the flanks of severe combined immunodeficiency mice in order to evaluate the CSC fraction.Results: Production of CEA by LoVo cells was stimulated by the addition of anticancer drugs. Drug-resistant LoVo cells expressed lower levels of CSC markers, and LoVo cells treated with any of the anticancer drugs tested did not generate tumors within 8 weeks from when the cells were injected subcutaneously into severe combined immunodeficiency mice. These results suggest that the drug-resistant LoVo cells have a smaller population of CSCs than the untreated LoVo cells.Conclusion: Production of CEA by LoVo cells can be stimulated by the addition of anticancer drugs. The drug-resistant subpopulation of LoVo colon cancer cells could stimulate the production of CEA, but these cells did not act as CSCs in in vivo tumor generation experiments.
机译:目的:我们评估了LoVo人结肠癌细胞在含有抗癌药物的培养基中分泌的较高水平的癌胚抗原(CEA)。通过将皮下异种移植到小鼠中来分析耐药性LoVo细胞。这项研究的目的是评估在这项研究中分离出的耐药细胞是否是癌症引发细胞,也称为癌症干细胞(CSCs)。方法:在用0培养的LoVo细胞中研究了CEA的产生–10 mM的抗癌药物,我们评估了抗癌药物治疗刺激的LoVo细胞增加的CEA产生。还评估了抗癌药处理过的LoVo细胞中几种CSC标记的表达。抗癌药物治疗后,将LoVo细胞皮下注射到重度合并免疫缺陷小鼠的腹侧,以评估CSC分数。结果:通过加入抗癌药物刺激LoVo细胞产生CEA。耐药的LoVo细胞表达的CSC标记物水平较低,并且用任何一种测试的抗癌药物处理过的LoVo细胞在将细胞皮下注射入严重的联合免疫缺陷小鼠后的8周内都没有产生肿瘤。这些结果表明,耐药的LoVo细胞比未处理的LoVo细胞具有更少的CSCs。结论:通过添加抗癌药物可以刺激LoVo细胞产生CEA。 LoVo结肠癌细胞的耐药亚群可以刺激CEA的产生,但在体内肿瘤生成实验中,这些细胞不充当CSC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号